Longitude Capital
  • ABOUT
  • TEAM
  • PORTFOLIO
  • NEWS
  • CONTACT
  • LP LOGIN
Select Page

Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut Allergy

by mparnell | Jun 2, 2019 | Portfolio News

Aimmune Announces U.S. FDA Advisory Committee Meeting Date for AR101 for Peanut Allergy

by mparnell | May 16, 2019 | Portfolio News

Poseida Therapeutics Receives US FDA Orphan Drug Destination for P-BCMA-101 for the Treatment of Multiple Myeloma

by mparnell | May 13, 2019 | Portfolio News

Molecular Templates, Inc. Reports First Quarter 2019 Financial Results

by mparnell | May 13, 2019 | Portfolio News

Kala Pharmaceuticals Reports First Quarter 2019 Financial Results

by mparnell | May 9, 2019 | Portfolio News

« Older Entries
Next Entries »

Media Contact

Maggie Jamison

mjamison@longitudecapital.com

650-854-5700

  • Facebook
  • Twitter
  • Google
  • RSS
footer-logo

LP Login

© 2023 Longitude Capital. All rights reserved.
  • Privacy Policy
  • Disclaimer